

2022 Multidisciplinary Thyroid Cancer Symposium

Course Faculty Disclosures

All individuals in a position to control the content of this education activity including members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

The following relevant financial relationships were disclosed:

Naifa L. Busaidy, MD, FACP, FACE, receives grant/research support from Novartis through the National Comprehensive Cancer Network. She is also a consultant for Eisai and Exelixis.

Umamaheswar Duvvuri, MD, PhD, is a consultant for Activ Surgical and BioMarin Pharmaceutical Inc.

Yuri E. Nikiforov, MD, PhD, owns intellectual property related to ThyroSeq and received royalty through the University of Pittsburgh. He is a consultant for Sonic Healthcare USA.

Dan Paul Zandberg, MD, receives grant/research support (institutional) from Aduro Biotech, Inc., Astellas Pharma, Inc., AstraZeneca, Bicara Therapeutics, Inc., Bristol-Myers Squibb, Checkmate Pharmaceuticals, Eli Lilly and Company, GlaxoSmithKline, MacroGenics, Inc., Merck, and Novasenta. He is a consultant for MacroGenics, Inc. and served on the advisory board for Blueprint Medicines and Prelude Therapeutics.

**UPMC | HILLMAN
CANCER CENTER**

No other planners, members of the planning committee, speakers, presenters, authors, content reviewers, and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.